Clinical Trial

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-19; most recent amendment 2026-01-15.
Status change: Recruiting → Active, Not Recruiting 2026-01-15
Trial Details
NCT Number NCT07142811
Lead Sponsor Vir Biotechnology, Inc.
Conditions Viral Hepatitis
Enrollment 100 participants
Start Date 2025-08-05
Primary Completion 2026-11 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-16